Physician profile
Saba Radhi
NPI 1851583751
$1,107.68
in general payments reported to CMS, 2019-2025
22 companies · $165 in 2025
The $165 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $271 · 2020: $128 · 2021: $11.92 · 2024: $532 · 2025: $165.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $697.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $696.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $150.00 | 2024 | |
| Lilly USA, LLC | $147.40 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $121.82 | 2024 | Libtayo |
| Daiichi Sankyo INC. | $117.22 | 2024-2025 | Datroway, Enhertu |
| Janssen Biotech, INC. | $117.17 | 2024 | Rybrevant |
| Astellas Pharma US INC | $99.00 | 2020 | |
| Abbvie INC. | $86.04 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $44.75 | 2019-2020 | |
| Ipsen Biopharmaceuticals, INC | $32.98 | 2019 | |
| Puma Biotechnology, INC. | $32.42 | 2019 | |
| Caris Mpi, INC. | $28.95 | 2025 | Mi Cancer Seek |
| Pharmacosmos Therapeutics INC. | $22.82 | 2024 | Cosela |
| Novocure INC. | $19.17 | 2024 | Optune Lua (Novottf-200t) |
| Springworks Therapeutics, INC. | $18.75 | 2024 | Ogsiveo |
| Genzyme Corporation | $15.31 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tempus Ai, INC | $14.95 | 2025 | Xt Cdx |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.99 | 2020 | |
| Sun Pharmaceutical Industries INC. | $13.02 | 2019 | |
| Gilead Sciences, INC. | $11.92 | 2021 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Saba Radhi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.